Shineco, Inc. (SISI)
USD 0.87
(-3.32%)
USD 0.87
(-3.32%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -17.06 Million USD | -94.87% |
| 2023 | -8.75 Million USD | 61.94% |
| 2022 | -23.01 Million USD | -7.46% |
| 2021 | -21.41 Million USD | -513.62% |
| 2020 | -3.48 Million USD | -1206.36% |
| 2019 | 315.41 Thousand USD | -96.6% |
| 2018 | 9.27 Million USD | 24.52% |
| 2017 | 7.44 Million USD | 1.43% |
| 2016 | 7.34 Million USD | 12.9% |
| 2015 | 6.5 Million USD | -8.52% |
| 2014 | 7.1 Million USD | 1.16% |
| 2013 | 7.02 Million USD | 0.0% |
| 2006 | 445.88 Thousand USD | -0.09% |
| 2005 | 446.3 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -3.22 Million USD | 40.1% |
| 2024 Q1 | -3.23 Million USD | -85.23% |
| 2024 Q2 | -5.38 Million USD | -66.65% |
| 2024 Q4 | -5.22 Million USD | -61.85% |
| 2023 Q1 | -1.81 Million USD | 75.27% |
| 2023 Q2 | -2.44 Million USD | -34.82% |
| 2023 Q4 | -1.74 Million USD | 32.36% |
| 2023 Q3 | -2.57 Million USD | -5.6% |
| 2023 FY | -8.75 Million USD | 61.94% |
| 2022 Q2 | -2.5 Million USD | 76.04% |
| 2022 FY | -23.01 Million USD | -7.46% |
| 2022 Q1 | -10.45 Million USD | -111.27% |
| 2022 Q4 | -7.32 Million USD | -168.68% |
| 2022 Q3 | -2.72 Million USD | -8.89% |
| 2021 Q2 | -9.46 Million USD | -900.56% |
| 2021 Q1 | -945.78 Thousand USD | -153.15% |
| 2021 Q3 | -6.05 Million USD | 36.0% |
| 2021 Q4 | -4.94 Million USD | 18.32% |
| 2021 FY | -21.41 Million USD | -513.62% |
| 2020 Q1 | -1.83 Million USD | -427.91% |
| 2020 Q2 | 199.4 Thousand USD | 110.86% |
| 2020 Q3 | -3.63 Million USD | -1921.37% |
| 2020 Q4 | 1.77 Million USD | 149.0% |
| 2020 FY | -3.48 Million USD | -1206.36% |
| 2019 Q4 | 560.1 Thousand USD | 140.63% |
| 2019 Q3 | -1.37 Million USD | -351.8% |
| 2019 FY | 315.41 Thousand USD | -96.6% |
| 2019 Q1 | 386.4 Thousand USD | -66.6% |
| 2019 Q2 | 547.48 Thousand USD | 41.69% |
| 2018 Q4 | 1.15 Million USD | -70.47% |
| 2018 FY | 9.27 Million USD | 24.52% |
| 2018 Q3 | 3.91 Million USD | 20.95% |
| 2018 Q2 | 3.23 Million USD | 238.15% |
| 2018 Q1 | 957.88 Thousand USD | -56.29% |
| 2017 Q4 | 2.19 Million USD | 31.49% |
| 2017 Q1 | 1.06 Million USD | -20.98% |
| 2017 Q2 | 2.52 Million USD | 138.19% |
| 2017 Q3 | 1.66 Million USD | -34.04% |
| 2017 FY | 7.44 Million USD | 1.43% |
| 2016 Q3 | 1.34 Million USD | -60.24% |
| 2016 Q1 | 1.4 Million USD | 102.61% |
| 2016 Q4 | 1.34 Million USD | -0.3% |
| 2016 FY | 7.34 Million USD | 12.9% |
| 2016 Q2 | 3.38 Million USD | 140.27% |
| 2015 FY | 6.5 Million USD | -8.52% |
| 2015 Q4 | 695.62 Thousand USD | -57.57% |
| 2015 Q3 | 1.63 Million USD | -39.67% |
| 2015 Q2 | 2.71 Million USD | 87.35% |
| 2015 Q1 | 1.45 Million USD | -26.33% |
| 2014 Q4 | 1.96 Million USD | 81.66% |
| 2014 Q2 | 2.06 Million USD | -0.0% |
| 2014 Q3 | 1.08 Million USD | -47.51% |
| 2014 Q1 | 2.06 Million USD | -19.0% |
| 2014 FY | 7.1 Million USD | 1.16% |
| 2013 Q4 | 2.54 Million USD | 40.19% |
| 2013 FY | 7.02 Million USD | 0.0% |
| 2013 Q3 | 1.81 Million USD | 0.0% |
| 2007 Q3 | 109.29 Thousand USD | 0.0% |
| 2007 Q1 | 32.61 Thousand USD | 0.0% |
| 2006 Q3 | 76.07 Thousand USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | 445.88 Thousand USD | -0.09% |
| 2005 FY | 446.3 Thousand USD | 0.0% |
| 2005 Q3 | 133.01 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 136.333% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | -13.004% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 110.221% |
| Cosmos Health Inc. | -21.83 Million USD | 21.828% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 14.884% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 89.03% |
| Cronos Group Inc. | -81.37 Million USD | 79.028% |
| Incannex Healthcare Limited | -30.04 Million USD | 43.191% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 56.412% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 282.894% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -260.288% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -256.631% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -256.631% |
| SCYNEXIS, Inc. | 72.66 Million USD | 123.484% |
| Safety Shot Inc | -12.18 Million USD | -40.066% |
| Theratechnologies Inc. | -10.62 Million USD | -60.59% |
| Alpha Teknova, Inc. | -35.56 Million USD | 52.012% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -383.895% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 119.465% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -263.026% |
| Dynavax Technologies Corporation | -37.02 Million USD | 53.911% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 108.164% |
| Radius Health, Inc. | -3.92 Million USD | -334.799% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -578.505% |
| Alvotech | -354.86 Million USD | 95.191% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 89.292% |
| SIGA Technologies, Inc. | 83.62 Million USD | 120.409% |
| Silver Spike Investment Corp. | 7.34 Million USD | 332.502% |
| Journey Medical Corporation | -2.07 Million USD | -723.245% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | -25.324% |
| Embecta Corp. | 221.5 Million USD | 107.705% |
| Harrow Health, Inc. | 580 Thousand USD | 3042.392% |
| Procaps Group, S.A. | 38.97 Million USD | 143.789% |
| Biofrontera Inc. | -22.67 Million USD | 24.744% |
| DURECT Corporation | -36.88 Million USD | 53.731% |
| PainReform Ltd. | -9.58 Million USD | -78.066% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -223.892% |
| OptiNose, Inc. | -22.74 Million USD | 24.979% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 235.1% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 236.254% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -174.776% |
| ProPhase Labs, Inc. | -21.61 Million USD | 21.039% |
| Phibro Animal Health Corporation | 53.31 Million USD | 132.01% |
| Procaps Group S.A. | 52.32 Million USD | 132.616% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -100.233% |
| Viatris Inc. | 766.2 Million USD | 102.227% |
| Rockwell Medical, Inc. | -6.67 Million USD | -155.86% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -224.817% |
| Tilray Brands, Inc. | -174.74 Million USD | 90.234% |
| PetIQ, Inc. | 60.01 Million USD | 128.436% |
| Talphera, Inc. | -16.88 Million USD | -1.047% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 106.802% |
| Alimera Sciences, Inc. | -1.47 Million USD | -1060.154% |
| Assertio Holdings, Inc. | -243.53 Million USD | 92.992% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -189.626% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 87.62% |
| Hempacco Co., Inc. | -8.81 Million USD | -93.66% |
| Alvotech | -354.86 Million USD | 95.191% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 104.68% |
| Kamada Ltd. | 10.06 Million USD | 269.573% |
| Currenc Group, Inc. | -6.64 Million USD | -156.792% |
| Indivior PLC | -4 Million USD | -326.647% |
| Evoke Pharma, Inc. | -7.43 Million USD | -129.661% |
| Flora Growth Corp. | -50.35 Million USD | 66.108% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 14.884% |
| Evolus, Inc. | -49.23 Million USD | 65.337% |
| HUTCHMED (China) Limited | 18.37 Million USD | 192.875% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 108.663% |
| Akanda Corp. | -10.05 Million USD | -69.786% |